Tagged: drug funding

Keytruda – The Tip of a Drug Funding Iceberg - Guest Work

Guest Author Feb 17, 2016

by Dr Francis Hunter Reminiscent of the furore surrounding public access to a one-year course of Herceptin, PHARMAC’s recent assignment of a low funding priority to pembrolizumab (Keytruda) for advanced melanoma has brought cancer drug funding back to the centre stage of national debate. Obfuscation from health minister Jonathon Coleman notwithstanding, the plight of metastatic melanoma patients … Read More

Is Keytruda cost-effective? - Public Health Expert

Public Health Expert Dec 15, 2015

Professor Tony Blakely Keytruda, or Pembrolizumab, is a new immune inhibitor drug that appears to have pronounced effectiveness in slowing – even reversing – disease progression in patients with advanced melanoma. It has received much media attention in recent months, and even calls from politicians to over-rule the PHARMAC process (currently PHARMAC do not recommend funding). In this blog … Read More